Global Depression Therapeutics- Market

Depression Therapeutics- Comprehensive Study by Indication Type (Major depressive disorder (MDD), Bipolar disorder, Dysthymic disorder, Postpartum depression, Seasonal affective disorder (SAD), Premenstrual dysphoric disorder (PMDD), Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), Drug Type (Antidepressants, Atypical Antidepressants, Antipsychotics, Others) Players and Region - Global Market Outlook to 2030

Depression Therapeutics- Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Depression Therapeutics- Market Scope
Depression is a mental health condition that causes a chronic feeling of emptiness, sadness, or an inability to feel pleasure that may appear to happen for no clear reason. Depression is a common mental health condition that causes a persistent feeling of sadness and changes in how you think, sleep, eat, and act. Depression can cause a range of psychological and physical symptoms, including decreased energy or fatigue, difficulty sleeping or oversleeping, and a persistent depressed mood. There are various therapy types used: cognitive behavioral therapy, interpersonal therapy, mindfulness-based therapies, dialectical behavior therapy, and psychodynamic therapy.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAlto Neuroscience, Inc.(Germany), Lindus Health (United States), Eli Lilly and Company (United States), Photopharmics (United States), Neumora Therapeutics (United States), Compass Pathways (United Kingdom), Meru Health (United States), InteraXon (Canada), Brightline (United States), Vida Health (United States), Atai Life Sciences (Germany) and Addex Therapeutics (Switzerland)
CAGR20.3%


Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Depression Therapeutics- market throughout the predicted period.

Alto Neuroscience, Inc.(Germany), Lindus Health (United States), Eli Lilly and Company (United States), Photopharmics (United States), Neumora Therapeutics (United States), Compass Pathways (United Kingdom), Meru Health (United States), InteraXon (Canada), Brightline (United States), Vida Health (United States), Atai Life Sciences (Germany) and Addex Therapeutics (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Phagenesis (United Kingdom), Blueprint (Canada), aiberry (United States), Neuromod Devices (Ireland), Circular Genomics (United States) and Gilgamesh Pharmaceuticals (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Depression Therapeutics- market by Type and Region with country level break-up.

On the basis of geography, the market of Depression Therapeutics- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In December 2021, Pear Therapeutics, Inc. acquired and/or licensed two new digital therapeutic assets, from Waypoint Health Innovations, LLC and a researcher named Fredrik Hollandale of Örebro University, that are designed for the treatment of a spectrum of depression conditions. Pear intends to leverage these two new assets to expand its depression product candidate to treat mild, moderate, severe, and treatment-refractory depression.
In October 2021 atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications


Influencing Trend:
Increase in national outpatient medical care expenditures

Market Growth Drivers:
The rising awareness about mental health, the development of infrastructure, Increasing awareness of mental health disorder and The increasing prevalence of depression, anxiety and mental health concerns

Challenges:
Drug recalls, and side effects associated to depression therapies and Lack of qualified, trained and skilled medical professionals

Restraints:
High Cost of treatment

Opportunities:
Governments are trying to increase the funding for mental health services and the treatment of mental illness, Growing funding from several government organizations and Increased prevalence of product launches

Key Target Audience
Reasearch Organizations, Government regulations and bodies, Research Industries and Others

Report Objectives / Segmentation Covered

By Application
By Indication Type
  • Major depressive disorder (MDD)
  • Bipolar disorder
  • Dysthymic disorder
  • Postpartum depression
  • Seasonal affective disorder (SAD)
  • Premenstrual dysphoric disorder (PMDD)
  • Others

By End Users
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Drug Type
  • Antidepressants
  • Atypical Antidepressants
  • Antipsychotics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rising awareness about mental health, the development of infrastructure
      • 3.2.2. Increasing awareness of mental health disorder
      • 3.2.3. The increasing prevalence of depression, anxiety and mental health concerns
    • 3.3. Market Challenges
      • 3.3.1. Drug recalls, and side effects associated to depression therapies
      • 3.3.2. Lack of qualified, trained and skilled medical professionals
    • 3.4. Market Trends
      • 3.4.1. Increase in national outpatient medical care expenditures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Depression Therapeutics-, by Indication Type, End Users, Distribution Channel, Drug Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Depression Therapeutics- (Value)
      • 5.2.1. Global Depression Therapeutics- by: Indication Type (Value)
        • 5.2.1.1. Major depressive disorder (MDD)
        • 5.2.1.2. Bipolar disorder
        • 5.2.1.3. Dysthymic disorder
        • 5.2.1.4. Postpartum depression
        • 5.2.1.5. Seasonal affective disorder (SAD)
        • 5.2.1.6. Premenstrual dysphoric disorder (PMDD)
        • 5.2.1.7. Others
      • 5.2.2. Global Depression Therapeutics- by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Homecare
        • 5.2.2.3. Specialty Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Depression Therapeutics- by: Distribution Channel (Value)
        • 5.2.3.1. Hospital pharmacies
        • 5.2.3.2. Retail pharmacies
        • 5.2.3.3. Online pharmacies
      • 5.2.4. Global Depression Therapeutics- Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Depression Therapeutics-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alto Neuroscience, Inc.(Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lindus Health (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Photopharmics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Neumora Therapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Compass Pathways (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Meru Health (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. InteraXon (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Brightline (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Vida Health (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Atai Life Sciences (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Addex Therapeutics (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Depression Therapeutics- Sale, by Indication Type, End Users, Distribution Channel, Drug Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Depression Therapeutics- (Value)
      • 7.2.1. Global Depression Therapeutics- by: Indication Type (Value)
        • 7.2.1.1. Major depressive disorder (MDD)
        • 7.2.1.2. Bipolar disorder
        • 7.2.1.3. Dysthymic disorder
        • 7.2.1.4. Postpartum depression
        • 7.2.1.5. Seasonal affective disorder (SAD)
        • 7.2.1.6. Premenstrual dysphoric disorder (PMDD)
        • 7.2.1.7. Others
      • 7.2.2. Global Depression Therapeutics- by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Homecare
        • 7.2.2.3. Specialty Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Depression Therapeutics- by: Distribution Channel (Value)
        • 7.2.3.1. Hospital pharmacies
        • 7.2.3.2. Retail pharmacies
        • 7.2.3.3. Online pharmacies
      • 7.2.4. Global Depression Therapeutics- Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Depression Therapeutics-: by Indication Type(USD Million)
  • Table 2. Depression Therapeutics- Major depressive disorder (MDD) , by Region USD Million (2018-2023)
  • Table 3. Depression Therapeutics- Bipolar disorder , by Region USD Million (2018-2023)
  • Table 4. Depression Therapeutics- Dysthymic disorder , by Region USD Million (2018-2023)
  • Table 5. Depression Therapeutics- Postpartum depression , by Region USD Million (2018-2023)
  • Table 6. Depression Therapeutics- Seasonal affective disorder (SAD) , by Region USD Million (2018-2023)
  • Table 7. Depression Therapeutics- Premenstrual dysphoric disorder (PMDD) , by Region USD Million (2018-2023)
  • Table 8. Depression Therapeutics- Others , by Region USD Million (2018-2023)
  • Table 9. Depression Therapeutics-: by End Users(USD Million)
  • Table 10. Depression Therapeutics- Hospitals , by Region USD Million (2018-2023)
  • Table 11. Depression Therapeutics- Homecare , by Region USD Million (2018-2023)
  • Table 12. Depression Therapeutics- Specialty Clinics , by Region USD Million (2018-2023)
  • Table 13. Depression Therapeutics- Others , by Region USD Million (2018-2023)
  • Table 14. Depression Therapeutics-: by Distribution Channel(USD Million)
  • Table 15. Depression Therapeutics- Hospital pharmacies , by Region USD Million (2018-2023)
  • Table 16. Depression Therapeutics- Retail pharmacies , by Region USD Million (2018-2023)
  • Table 17. Depression Therapeutics- Online pharmacies , by Region USD Million (2018-2023)
  • Table 18. South America Depression Therapeutics-, by Country USD Million (2018-2023)
  • Table 19. South America Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 20. South America Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 21. South America Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 22. South America Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 23. Brazil Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 24. Brazil Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 25. Brazil Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 26. Brazil Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 27. Argentina Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 28. Argentina Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 29. Argentina Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 30. Argentina Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 31. Rest of South America Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 32. Rest of South America Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 33. Rest of South America Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 34. Rest of South America Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 35. Asia Pacific Depression Therapeutics-, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 37. Asia Pacific Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 38. Asia Pacific Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 39. Asia Pacific Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 40. China Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 41. China Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 42. China Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 43. China Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 44. Japan Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 45. Japan Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 46. Japan Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 47. Japan Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 48. India Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 49. India Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 50. India Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 51. India Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 52. South Korea Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 53. South Korea Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 54. South Korea Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 55. South Korea Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 56. Taiwan Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 57. Taiwan Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 58. Taiwan Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 59. Taiwan Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 60. Australia Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 61. Australia Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 62. Australia Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 63. Australia Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 68. Europe Depression Therapeutics-, by Country USD Million (2018-2023)
  • Table 69. Europe Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 70. Europe Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 71. Europe Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 72. Europe Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 73. Germany Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 74. Germany Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 75. Germany Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 76. Germany Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 77. France Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 78. France Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 79. France Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 80. France Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 81. Italy Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 82. Italy Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 83. Italy Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 84. Italy Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 85. United Kingdom Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 86. United Kingdom Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 87. United Kingdom Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 88. United Kingdom Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 89. Netherlands Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 90. Netherlands Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 91. Netherlands Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 92. Netherlands Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 93. Rest of Europe Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 94. Rest of Europe Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 95. Rest of Europe Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 96. Rest of Europe Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 97. MEA Depression Therapeutics-, by Country USD Million (2018-2023)
  • Table 98. MEA Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 99. MEA Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 100. MEA Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 101. MEA Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 102. Middle East Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 103. Middle East Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 104. Middle East Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 105. Middle East Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 106. Africa Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 107. Africa Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 108. Africa Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 109. Africa Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 110. North America Depression Therapeutics-, by Country USD Million (2018-2023)
  • Table 111. North America Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 112. North America Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 113. North America Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 114. North America Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 115. United States Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 116. United States Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 117. United States Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 118. United States Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 119. Canada Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 120. Canada Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 121. Canada Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 122. Canada Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 123. Mexico Depression Therapeutics-, by Indication Type USD Million (2018-2023)
  • Table 124. Mexico Depression Therapeutics-, by End Users USD Million (2018-2023)
  • Table 125. Mexico Depression Therapeutics-, by Distribution Channel USD Million (2018-2023)
  • Table 126. Mexico Depression Therapeutics-, by Drug Type USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Depression Therapeutics-: by Indication Type(USD Million)
  • Table 140. Depression Therapeutics- Major depressive disorder (MDD) , by Region USD Million (2025-2030)
  • Table 141. Depression Therapeutics- Bipolar disorder , by Region USD Million (2025-2030)
  • Table 142. Depression Therapeutics- Dysthymic disorder , by Region USD Million (2025-2030)
  • Table 143. Depression Therapeutics- Postpartum depression , by Region USD Million (2025-2030)
  • Table 144. Depression Therapeutics- Seasonal affective disorder (SAD) , by Region USD Million (2025-2030)
  • Table 145. Depression Therapeutics- Premenstrual dysphoric disorder (PMDD) , by Region USD Million (2025-2030)
  • Table 146. Depression Therapeutics- Others , by Region USD Million (2025-2030)
  • Table 147. Depression Therapeutics-: by End Users(USD Million)
  • Table 148. Depression Therapeutics- Hospitals , by Region USD Million (2025-2030)
  • Table 149. Depression Therapeutics- Homecare , by Region USD Million (2025-2030)
  • Table 150. Depression Therapeutics- Specialty Clinics , by Region USD Million (2025-2030)
  • Table 151. Depression Therapeutics- Others , by Region USD Million (2025-2030)
  • Table 152. Depression Therapeutics-: by Distribution Channel(USD Million)
  • Table 153. Depression Therapeutics- Hospital pharmacies , by Region USD Million (2025-2030)
  • Table 154. Depression Therapeutics- Retail pharmacies , by Region USD Million (2025-2030)
  • Table 155. Depression Therapeutics- Online pharmacies , by Region USD Million (2025-2030)
  • Table 156. South America Depression Therapeutics-, by Country USD Million (2025-2030)
  • Table 157. South America Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 158. South America Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 159. South America Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 160. South America Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 161. Brazil Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 162. Brazil Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 163. Brazil Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 164. Brazil Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 165. Argentina Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 166. Argentina Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 167. Argentina Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 168. Argentina Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 169. Rest of South America Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 170. Rest of South America Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 171. Rest of South America Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 172. Rest of South America Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 173. Asia Pacific Depression Therapeutics-, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 175. Asia Pacific Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 176. Asia Pacific Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 177. Asia Pacific Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 178. China Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 179. China Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 180. China Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 181. China Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 182. Japan Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 183. Japan Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 184. Japan Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 185. Japan Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 186. India Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 187. India Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 188. India Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 189. India Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 190. South Korea Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 191. South Korea Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 192. South Korea Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 193. South Korea Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 194. Taiwan Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 195. Taiwan Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 196. Taiwan Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 197. Taiwan Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 198. Australia Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 199. Australia Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 200. Australia Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 201. Australia Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 206. Europe Depression Therapeutics-, by Country USD Million (2025-2030)
  • Table 207. Europe Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 208. Europe Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 209. Europe Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 210. Europe Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 211. Germany Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 212. Germany Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 213. Germany Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 214. Germany Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 215. France Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 216. France Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 217. France Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 218. France Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 219. Italy Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 220. Italy Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 221. Italy Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 222. Italy Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 223. United Kingdom Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 224. United Kingdom Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 225. United Kingdom Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 226. United Kingdom Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 227. Netherlands Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 228. Netherlands Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 229. Netherlands Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 230. Netherlands Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 231. Rest of Europe Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 232. Rest of Europe Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 233. Rest of Europe Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 234. Rest of Europe Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 235. MEA Depression Therapeutics-, by Country USD Million (2025-2030)
  • Table 236. MEA Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 237. MEA Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 238. MEA Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 239. MEA Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 240. Middle East Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 241. Middle East Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 242. Middle East Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 243. Middle East Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 244. Africa Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 245. Africa Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 246. Africa Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 247. Africa Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 248. North America Depression Therapeutics-, by Country USD Million (2025-2030)
  • Table 249. North America Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 250. North America Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 251. North America Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 252. North America Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 253. United States Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 254. United States Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 255. United States Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 256. United States Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 257. Canada Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 258. Canada Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 259. Canada Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 260. Canada Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 261. Mexico Depression Therapeutics-, by Indication Type USD Million (2025-2030)
  • Table 262. Mexico Depression Therapeutics-, by End Users USD Million (2025-2030)
  • Table 263. Mexico Depression Therapeutics-, by Distribution Channel USD Million (2025-2030)
  • Table 264. Mexico Depression Therapeutics-, by Drug Type USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Depression Therapeutics-: by Indication Type USD Million (2018-2023)
  • Figure 5. Global Depression Therapeutics-: by End Users USD Million (2018-2023)
  • Figure 6. Global Depression Therapeutics-: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Depression Therapeutics- Share (%), by Country
  • Figure 8. Asia Pacific Depression Therapeutics- Share (%), by Country
  • Figure 9. Europe Depression Therapeutics- Share (%), by Country
  • Figure 10. MEA Depression Therapeutics- Share (%), by Country
  • Figure 11. North America Depression Therapeutics- Share (%), by Country
  • Figure 12. Global Depression Therapeutics- share by Players 2023 (%)
  • Figure 13. Global Depression Therapeutics- share by Players (Top 3) 2023(%)
  • Figure 14. Global Depression Therapeutics- share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Alto Neuroscience, Inc.(Germany) Revenue, Net Income and Gross profit
  • Figure 17. Alto Neuroscience, Inc.(Germany) Revenue: by Geography 2023
  • Figure 18. Lindus Health (United States) Revenue, Net Income and Gross profit
  • Figure 19. Lindus Health (United States) Revenue: by Geography 2023
  • Figure 20. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 22. Photopharmics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Photopharmics (United States) Revenue: by Geography 2023
  • Figure 24. Neumora Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Neumora Therapeutics (United States) Revenue: by Geography 2023
  • Figure 26. Compass Pathways (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Compass Pathways (United Kingdom) Revenue: by Geography 2023
  • Figure 28. Meru Health (United States) Revenue, Net Income and Gross profit
  • Figure 29. Meru Health (United States) Revenue: by Geography 2023
  • Figure 30. InteraXon (Canada) Revenue, Net Income and Gross profit
  • Figure 31. InteraXon (Canada) Revenue: by Geography 2023
  • Figure 32. Brightline (United States) Revenue, Net Income and Gross profit
  • Figure 33. Brightline (United States) Revenue: by Geography 2023
  • Figure 34. Vida Health (United States) Revenue, Net Income and Gross profit
  • Figure 35. Vida Health (United States) Revenue: by Geography 2023
  • Figure 36. Atai Life Sciences (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Atai Life Sciences (Germany) Revenue: by Geography 2023
  • Figure 38. Addex Therapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Addex Therapeutics (Switzerland) Revenue: by Geography 2023
  • Figure 40. Global Depression Therapeutics-: by Indication Type USD Million (2025-2030)
  • Figure 41. Global Depression Therapeutics-: by End Users USD Million (2025-2030)
  • Figure 42. Global Depression Therapeutics-: by Distribution Channel USD Million (2025-2030)
  • Figure 43. South America Depression Therapeutics- Share (%), by Country
  • Figure 44. Asia Pacific Depression Therapeutics- Share (%), by Country
  • Figure 45. Europe Depression Therapeutics- Share (%), by Country
  • Figure 46. MEA Depression Therapeutics- Share (%), by Country
  • Figure 47. North America Depression Therapeutics- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alto Neuroscience, Inc.(Germany)
  • Lindus Health (United States)
  • Eli Lilly and Company (United States)
  • Photopharmics (United States)
  • Neumora Therapeutics (United States)
  • Compass Pathways (United Kingdom)
  • Meru Health (United States)
  • InteraXon (Canada)
  • Brightline (United States)
  • Vida Health (United States)
  • Atai Life Sciences (Germany)
  • Addex Therapeutics (Switzerland)
Additional players considered in the study are as follows:
Phagenesis (United Kingdom) , Blueprint (Canada) , aiberry (United States) , Neuromod Devices (Ireland) , Circular Genomics (United States) , Gilgamesh Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 219 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Depression Therapeutics- Market Quantitative research analysis
Global Depression Therapeutics- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Depression Therapeutics- Market are by end use application [].
The Depression Therapeutics- Market is gaining popularity and expected to see strong valuation by 2030.
  • The rising awareness about mental health, the development of infrastructure
  • Increasing awareness of mental health disorder
  • The increasing prevalence of depression, anxiety and mental health concerns

Know More About Global Depression Therapeutics- Market Report?

Have a Query? Click Here

Other Related Reports

Ischemic stroke Comprehensive Study by Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, Others), Treatment Type (Tissue Plasminogen Activator, Anticoagulant, A...
$ 3800
Cardiovascular Application Comprehensive Study by Type (Diagnostic and Monitoring Devices, (Electrocardiogram, Holter Monitors, Event Monitors, Others), Interventional Devices, (Coronary Stents, Cath...
$ 3800
Membranous Nephropathy Comprehensive Study by Type (Primary Membranous Nephropathy (Idiopathic), Secondary Membranous Nephropathy), Age Group (Children, Adults), Treatment Type (Biologics, Pharmaceut...
$ 3800
Malocclusion Comprehensive Study by Type (Overcrowding, Spacing, Openbite, Overjet, Overbite, Underbite, Crossbite, Diastema, Impacted Tooth, Missing Tooth), Age Group (Children, Adults), Treatment T...
$ 3800
Orphan Diseases Comprehensive Study by Disease Type (Oncology, Allergic and Immunologic Disorders, Cardiac and Vascular Conditions, Infectious Diseases, Neurologic Conditions, Skin and Soft Tissue Co...
$ 3800